Understanding how to improve treatment for metastatic triple-negative breast cancer
Decoding the Heterogeneity in Chemo-Immunomodulation to Unlock the Potential of Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer
This study is looking at ways to improve treatment for people with metastatic triple-negative breast cancer by finding the best combinations of chemotherapy and immunotherapy, so if you're a patient with this type of cancer, you might have the chance to try new treatment options that could work better for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10933411 on NIH RePORTER |
What this research studies
This research focuses on metastatic triple-negative breast cancer (mTNBC), a particularly aggressive form of breast cancer with poor survival rates. The study aims to enhance the effectiveness of chemoimmunotherapy by identifying the best chemotherapy agents that work in synergy with PD-1 blockade, a type of immunotherapy. By analyzing the heterogeneity of mTNBC, the researchers hope to tailor treatment strategies to individual patients, potentially leading to better outcomes. Patients may be involved in trials that test these new treatment combinations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with non-metastatic breast cancer or those with other subtypes of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment responses for patients with metastatic triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results with chemoimmunotherapy in other solid tumors, indicating potential for success in this novel approach for mTNBC.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Gbadamosi, Mohammed Olusoji — University of Florida
- Study coordinator: Gbadamosi, Mohammed Olusoji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.